Dexcom (DXCM) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dexcom’s 2025 Share Repurchase Program, authorized by its Board of Directors, aims to buy back up to $750 million of its common stock by June 30, 2026. However, the program’s success in enhancing long-term share value is uncertain due to potential market volatility and other factors such as unfavorable market conditions and strategic opportunities. The company retains discretion over the timing and amount of repurchases, which may impact stock price and earnings per share. As of September 30, 2025, Dexcom has repurchased 2.4 million shares for $187.2 million, but the program’s future impact remains unpredictable.
The average DXCM stock price target is $90.33, implying 55.15% upside potential.
To learn more about Dexcom’s risk factors, click here.